Ranibizumab

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Choroidal Neovascularization Secondary to Pathologic Myopia

Conditions

Choroidal Neovascularization Secondary to Pathologic Myopia

Trial Timeline

Jun 10, 2014 → Jul 15, 2016

NCT ID

NCT02034006

About Ranibizumab

Ranibizumab is a phase 3 stage product being developed by Novartis for Choroidal Neovascularization Secondary to Pathologic Myopia. The current trial status is completed. This product is registered under clinical trial identifier NCT02034006. Target conditions include Choroidal Neovascularization Secondary to Pathologic Myopia.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04464694	Approved	UNKNOWN	Sep 1, 2020	Jun 1, 2022	Proliferative Diabetic Retinopathy
NCT02953938	Approved	Completed	Dec 15, 2016	Dec 28, 2018	Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
NCT02976194	Approved	UNKNOWN	Nov 22, 2016	Jan 1, 2020	Exudative Age-related Macular Degeneration
NCT02843490	Approved	Completed	Aug 5, 2016	Nov 9, 2017	Neovascular Age-related Macular Degeneration
NCT02640664	Phase 3	Completed	Jun 16, 2016	Apr 21, 2022	Retinopathy of Prematurity (ROP)
NCT02707575	Pre-clinical	Completed	Apr 26, 2016	Apr 23, 2018	Age-related Macular Degeneration
NCT02634970	Approved	Withdrawn	Mar 1, 2016	Dec 1, 2017	Wet Age-related Macular Degeneration (Wet AMD)
NCT02375971	Phase 3	Completed	Dec 30, 2015	Dec 14, 2017	Retinopathy of Prematurity
NCT02329132	Pre-clinical	Completed	Nov 1, 2015	Feb 28, 2018	Diabetic Macular Edema
NCT02161575	Approved	Completed	Aug 28, 2014	Sep 14, 2017	Neovascular Age-related Macular Degeneration
NCT02034006	Phase 3	Completed	Jun 10, 2014	Jul 15, 2016	Choroidal Neovascularization Secondary to Pathologic Myopia
NCT02059772	Approved	UNKNOWN	Apr 30, 2014	Dec 31, 2017	Diabetic Macular Edema
NCT01986907	Approved	Completed	Mar 4, 2014	Jun 15, 2016	Wet Age Related Macular Degeneration
NCT02055911	Approved	Withdrawn	Mar 1, 2014	Jul 1, 2015	Diabetic Macular Edema
NCT02478515	Approved	Completed	Jan 1, 2014	Mar 1, 2019	Branch Retinal Vein Occlusion
NCT01972789	Approved	Completed	Oct 31, 2013	Feb 28, 2017	Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD
NCT01846299	Phase 3	Completed	Oct 1, 2013	Sep 1, 2015	Macular Edema (ME)
NCT01908816	Phase 3	Completed	Sep 26, 2013	Jan 8, 2016	Choroidal Neovascularization
NCT01840410	Phase 3	Completed	Sep 1, 2013	Nov 1, 2015	Choroidal Neovascularization (CNV)
NCT01780935	Phase 3	Completed	Jun 3, 2013	Jul 9, 2015	Neovascular Age-related Macular Degeneration

Competing Products

20 competing products in Choroidal Neovascularization Secondary to Pathologic Myopia

See all competitors

Product	Company	Stage	Hype Score
Zimura + Eylea	Astellas Pharma	Phase 2	52
Avacincaptad Pegol	Astellas Pharma	Phase 2	52
Verteporfin Photodynamic Therapy + Ranibizumab	Novartis	Approved	85
ranibizumab	Novartis	Approved	85
Ranibizumab	Novartis	Approved	85
Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT	Novartis	Phase 3	77
ranibizumab	Novartis	Phase 3	77
Everolimus + Ranibizumab	Novartis	Phase 2	52
Ranibizumab	Novartis	Phase 3	77
ranibizumab 0.5mg	Novartis	Phase 2	52
ranibizumab	Novartis	Phase 3	77
Brolucizumab 6mg + Brolucizumab 6mg	Novartis	Phase 3	77
Intravitreal injection ranibizumab	Novartis	Phase 2	52
Ranibizumab	Novartis	Phase 1/2	41
Faricimab + Ranibizumab + Sham Procedure	Roche	Phase 2	52
Faricimab + Ranibizumab	Roche	Phase 3	77
Faricimab + Ranibizumab + Sham Procedure	Roche	Phase 2	52
Intravitreal Pegaptanib	Pfizer	Pre-clinical	22
Intravitreal aflibercept injection 2.0mg	Regeneron Pharmaceuticals	Approved	84
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)	Regeneron Pharmaceuticals	Pre-clinical	22

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved